A 12-month, phase 3, open-label, multi-center study to evaluate the long-term safety of PN 400 [esomeprazole/naproxen] in subjects who are at risk for developing NSAID [non-steroidal anti-inflammatory drugs]-associated ulcers.

Trial Profile

A 12-month, phase 3, open-label, multi-center study to evaluate the long-term safety of PN 400 [esomeprazole/naproxen] in subjects who are at risk for developing NSAID [non-steroidal anti-inflammatory drugs]-associated ulcers.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2011

At a glance

  • Drugs Esomeprazole/naproxen (Primary)
  • Indications Arthritis; Musculoskeletal pain; NSAID-induced ulcer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2011 Results have been reported in an AstraZeneca media release.
    • 19 Mar 2010 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top